Lilly Settles on Cialis Patent, Pushing Generics to September 2018

Generic Line
A A
Eli Lilly & Co. settled with several generic companies to resolve pending litigation over a unit dose patent for Cialis (tadalafil), delaying potential ANDA competition.

To View This Article:

Login

Subscribe To Generic Line